HYPERTENSION MANAGEMENT AND STROKE PREVENTION ...
HYPERTENSION MANAGEMENT AND STROKE PREVENTION ... HYPERTENSION MANAGEMENT AND STROKE PREVENTION ...
18 Cumulative Event Rate 0.10 0.08 0.06 0.04 0.02 0.00 C: 15,268 D: 9,067 Heart Failure Rel Risk 2.04 doxazosin 95% CI 1.79-2.32 z = 10.95, p < 0.0001 Years of Follow-up ALLHAT chlorthalidone 9,541 5,531 2,427 13,644 5,457 3,089 1,351 0 1 7,845 2 3 4 JAMA. 2000;283:1967-1975
19 ALLHAT 100.0 80.0 60.0 % 40.0 20.0 0.0 On Step 1 or Equivalent Treatment by Antihypertensive Treatment Group 1 Year 2 Years 3 Years 4 Years 5 Years Chlor 87.1 84.7 82.7 80.8 80.5 Aml 87.6 85.2 83.2 80.5 80.4 Lis 82.4 78.4 77.1 74.8 72.6
- Page 1 and 2: HYPERTENSION MANAGEMENT AND STROKE
- Page 3 and 4: 3 Hypertension Treatment by Drug Cl
- Page 5 and 6: 5 ALLHAT Antihypertensive Trial Des
- Page 7 and 8: 7 ALLHAT Pre-Specified Outcomes All
- Page 9 and 10: 9 ALLHAT Inclusion Criteria for Ant
- Page 11 and 12: 11 ALLHAT ALLHAT Inclusion Criteria
- Page 13 and 14: 13 ALLHAT High-risk hypertensive pa
- Page 15 and 16: 15 ALLHAT Step 2 Agents: Reserpine
- Page 17: 17 Cumulative Event Rate 0.30 0.25
- Page 21 and 22: 21 ALLHAT mm Hg BP 150 145 140 135
- Page 23 and 24: 23 Percent ALLHAT 80 60 40 20 0 59
- Page 25 and 26: 25 ALLHAT Cumulative Stroke Rate .1
- Page 27 and 28: 27 ALLHAT Cumulative Mortality Rate
- Page 29 and 30: 29 ALLHAT Total 1.04 (0.99, 1.09) A
- Page 31 and 32: 31 ALLHAT Total 1.38 (1.25, 1.52) A
- Page 33 and 34: 33 ALLHAT AHT: TOTAL CHD AND ALL CA
- Page 35 and 36: 35 ALLHAT Antihypertensive Trial: I
- Page 38 and 39: 38 ALLHAT vs. ANBP-2 • Randomized
- Page 40 and 41: Primary Adjudicated Events - Ramipr
- Page 42 and 43: DOES OBSERVED BP REDUCTION ACCOUNT
- Page 44 and 45: Quartiles ≤124 125-139 140-150 15
- Page 46 and 47: SUBGROUP RESULTS BY OTHER DRUG THER
- Page 48 and 49: 48 Blood Pressure Classification BP
- Page 50 and 51: 50 New Features and Key Messages
- Page 52 and 53: 52 New Features and Key Messages (C
- Page 54 and 55: 54 Algorithm for Treatment of Stage
18<br />
Cumulative Event Rate<br />
0.10<br />
0.08<br />
0.06<br />
0.04<br />
0.02<br />
0.00<br />
C: 15,268<br />
D: 9,067<br />
Heart Failure<br />
Rel Risk<br />
2.04<br />
doxazosin<br />
95% CI<br />
1.79-2.32<br />
z = 10.95, p < 0.0001<br />
Years of Follow-up<br />
ALLHAT<br />
chlorthalidone<br />
9,541 5,531 2,427<br />
13,644<br />
5,457 3,089 1,351<br />
0 1<br />
7,845<br />
2 3 4<br />
JAMA. 2000;283:1967-1975
Change language